patients dosed by adjusted body weight were more likely to under-shoot the goal AUC (-12.8 % vs. +19.5 %, P ¼ .018), and require busulfan dose increases (+20% vs. -19.9%, P ¼ .012) compared to those dosed on actual body weight. A subgroup analysis confirmed this result for patients receiving Bu/Cy (-23.6 % vs. +2.2%, P ¼<.001 for goal AUC and +36.2% vs. -4.5 %, P ¼ .008 for busulfan dose changes in adjusted vs. actual body weight groups, respectively), but not Flu/Bu conditioning regimens (-0.8 % vs. +25.3%, P ¼ .123 for goal AUC and +3.4% vs. -25.1 %, P ¼ .174 for busulfan dose changes in adjusted vs. actual body weight groups, respectively). Notably, two patients dosed by actual body weight in the Flu/ Bu group experienced an AUC of > 9000 mmol * min. Time to neutrophil or platelet engraftment, progression-free survival and overall survival were not significantly different between those dosed on actual versus adjusted body weight (P > .05). No neurologic adverse events or VOD incidents were observed in any group. Conclusions: Our prospective analysis of IV busulfan PK data in various myeloablative and non-myeloablative busulfan based conditioning regimens for HSCT provides important insight into the choice of appropriate busulfan dosing weight. Further studies are warranted to elucidate which weight is most likely to achieve goal areaunder-the curve and subsequent optimal patient outcomes.
Background: Etoposide is an important drug in the conditioning regimen for hematopoietic stem cell transplant (HSCT). The administration of etoposide in this patient care setting presents a challenge due to limited aqueous solubility. As a result of the high doses utilized in myeloablative regimens, administration is accompanied by large volumes of intravenous fluids which increase the risk for volume overload, cardiac dysfunction, and electrolyte abnormalities. There are published reports that describe unchanged pharmacokinetic parameters between diluted and undiluted drug, as well as data describing the safe use of undiluted drug in the transplant population. Methods: We report our experience with eleven patients who received undiluted etoposide (20 mg/mL) over 4 hours through a central line in preparation for HSCT. All patients received an antihistamine and corticosteroid as premedication, as well as another dose of each and acetaminophen when half of the volume had infused. The etoposide was infused through DEHP-free tubing into a dedicated lumen. Vital signs were monitored at baseline, regularly throughout the infusion, and after the infusion was complete. Results: Between April 2 and June 15, 2012, eleven patients received undiluted etoposide at a dose of 60 mg/ kg. The most common adverse events documented were gastrointestinal toxicities. All patients reported nausea and most cases were accompanied by emesis, requiring an average of 4.4 antiemetic doses for treatment of breakthrough nausea/vomiting. Hypotension was documented in nine patients, with an average drop in systolic blood pressure of 35 mm Hg (range: 15-46 mm Hg) occurring 6.6 hours (range: 1.7-18.8 hours) after the start of etoposide infusion. Nine patients required fluid resuscitation with an average of 1400 mL (range: 500 mL-3500 mL) of normal saline. Conclusion: Despite published reports of successful administration of undiluted etoposide in myeloablative conditioning regimens, we report numerous adverse events in our patient population. All patients treated at our institution with undiluted etoposide as part of the conditioning regimen experienced side effects related to the drug. The benefits of administering undiluted etoposide should be carefully weighed against the possibility of related toxicities.
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Delaying Introduction: Antifungal prophylaxis with azoles is considered standard in patients undergoing allo-HCT. However, azoles have significant interactions with immunosuppressive drugs used for graft-versus-host disease (GVHD) prophylaxis. Since the risk of GVHD is increased in the setting of sub-therapeutic immunosuppressant levels, we changed our standard practice from initiating the triazole on day +3 to day +7 after allo-HCT in order to make the change at steady state and limit the occurrence of non-therapeutic levels. Methods: We retrospectively evaluated 196 patients treated from Jan 2009 to Nov 2011 to assess the impact of delaying the start of azole antifungals on immunosuppressive levels, acute GVHD, and rate of invasive fungal infections (IFI). Micafungin was given from admission until azole initiation. Patients received voriconazole (n¼162), posaconazole (n¼17), fluconazole (n¼9) or were maintained on micafungin (n¼8). Stem cell sources included PBSCT from related/unrelated donors (n¼139) and cord blood grafts (n¼57). GVHD prophylaxis was with tacrolimus (tacro) + sirolimus (siro) + methotrexate (MTX) (n¼76), tacro + MTX (n¼42), cyclosporine (CSA) + mycophenolate mofetil (MMF) (n¼57), tacro + MMF (n¼9), tacro + siro (n¼7), CSA + MTX (n¼3), CSA (n¼1), siro + MMF (n¼1). Results were analyzed by intent-to-treat (ITT) for patients treated before (day+3 switch, n¼69) or after February 2010 (day+7 switch, n¼127) as well as by actual day of switch + 1 (day+2,3,4: n¼49 vs. day+6,7,8: n¼70). Cumulative incidence (CI) functions estimated day 200 grade II-IV aGVHD. Gray's test was used to compare aGVHD incidence for individuals in the day +3 and day+7 treatment categories for both the ITT and as-treated analyses. Results: Median levels two weeks after HCT were therapeutic in 19/19 (100%), 50/52 (96%), 31/32 (97%) patients on CSA, Tacro, and Siro, respectively, prior to Feb 2010 and in 43/44 (98%), 82/83 (99%), 47/52 (90%), for CSA, Tacro, and Siro, respectively, after Feb 2010. ITT CI of aGVHD was 0.32 (95% CI: 0.21, 0.43) and 0.46 (95% CI: 0.37, 0.54) prior to and after Feb 2010, respectively (P¼ .11). Eighty-six patients (44%) were considered at high risk for IFI pre-HSCT by standard criteria. The rate of IFI post HCT was 9/69 (13%) and 18/127 (14%) prior to and after Feb 2010, respectively. Proven (n¼2) or probable (n¼2) IFI was only observed in 4 patients (2%), with the remainder having possible IFI. Subgroup analysis did not find any statistical difference between the two groups for aGVHD analyzed by stem cell source or IFI analyzed by pre-HSCT risk. In addition, there was no difference in the number of dose modifications required and when patients were analyzed by actual day of azole start. Conclusion: Delaying the start of triazole prophylaxis till 7 days after allo-HSCT does not affect outcomes, including achieving and maintaining therapeutic levels of GVHD prophylaxis, and incidence of aGVHD or IFI. 1 Pharmacy, Medical University of South Carolina, Charleston, SC; 2 Medicine, Medical University of South Carolina, Charleston, SC Cardiac arrhythmias (CA) can be an important complication of cellular therapy. We performed a retrospective, single center, comprehensive analysis to understand the risk factors, outcome and morbidity of cardiac arrhythmias developing in the first 100 days after allogeneic hematopoietic stem cell transplantation in adults. Overall 133 patients received an allogeneic transplant between 01/2008 and 07/2012 and were included in the analysis. Individuals with pre existing arrhythmias were excluded. Patients and transplant characteristics are detailed in Table 1 . At least one episode of cardiac arrhythmia developed in 25 individuals (18.8%, 95% C.I. 13.0-26.3%) with 19 individuals developing atrial flutter/fibrillation and 8 individuals developing AV nodal reentrant tachycardia. Median time of onset of the arrhythmia was 27 days (range 1-96) after transplant. Neither underlying disease, conditioning regimen, comorbidities, left ventricular ejection fraction, presence of ventricular diastolic dysfunction, prior use of beta blockers, calcium channel blockers, ACE inhibitors or ARBs were associated with higher risk of developing CA in univariate or multivariate analysis. Patients who developed CA were older (median age 56 years) than patients who did not develop CA (median age 51 years), but this difference was not statistically significant (P ¼ .08). Of the 25 individuals who developed CA, 13 died prior to day 100 (4 from cardiac causes). Among the remaining 12 patients, 8 had restoration of sinus rhythm by day 100. Median survival was 14+/-2 weeks for individuals who developed CA vs. 81 +/-35 weeks for patients who did not develop CA prior to 100 days (P < .0001). In multivariate analysis, development of CA prior to 100 days was a strong predictor of mortality (HR¼2.87, 95% C.I. 1.67-4.95, P ¼ .001) even when adjusted for age, intensity of the conditioning regimen, comorbidities, chronic medications, left ventricular ejection fraction and presence of ventricular diastolic dysfunction. We concluded that the development of CA after allogeneic transplantation is relatively common, but difficult to predict on the basis of patient and transplant characteristics, representing a strong and independent predictor of post transplant mortality. Allogeneic bone marrow transplant (BMT) patients with cyclosporine-induced hypertension are at risk of serious complications including intracerebral hemorrhage and seizures. There is little data describing cyclosporineinduced hypertension in the allogeneic BMT population. The aim of this study was to characterize cyclosporineinduced hypertension in the allogeneic BMT population at the Medical University of South Carolina (MUSC), while also investigating what blood pressure (BP) medications currently used may be most efficacious. We conducted a single center, IRB approved, retrospective study of patients receiving an allogeneic BMT from January 1, 2008 to August 31, 2011. Demographic data was collected for all patients. Those patients experiencing cyclosporineinduced hypertension had additional data recorded: number of systolic blood pressure (SBP) readings > 160 mmHG, number of diastolic blood pressure (DBP) readings >100 mmHg, addition of an antihypertensive medication, and number of doses and dosage administered. Safety was assessed through recording number of SBP readings < 100 mmHG, number of DBP readings < 40 mmHg, and the minimum heart rate (HR) while on cyclosporine. Twenty seven (27) of 78 patients were identified as experiencing 
